CLR 131: Ph II started

Cellectar began an open-label, U.S. Phase II trial to evaluate a single dose of 25 mCi/m2 IV CLR 131 plus once-weekly oral dexamethasone for up to 12 weeks in about 80 patients with hematologic malign...